Avantor (NYSE:AVTR) Lowered to Sell at Zacks Investment Research

Share on StockTwits

Avantor (NYSE:AVTR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “Avantor Inc. is a provider of critical products and services primarily to biopharma, healthcare, education & government, advanced technologies & applied materials industries. Avantor Inc. is based in Radnor, United States. “

A number of other analysts also recently commented on the company. Barclays reiterated a “buy” rating and issued a $22.00 price objective on shares of Avantor in a research report on Thursday, July 18th. Janney Montgomery Scott reiterated a “buy” rating and issued a $18.70 price objective (down previously from $27.00) on shares of Avantor in a research report on Wednesday, June 26th. Finally, Cleveland Research assumed coverage on Avantor in a research report on Friday, August 2nd. They issued a “neutral” rating for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have issued a buy rating to the stock. Avantor currently has a consensus rating of “Buy” and a consensus price target of $20.81.

NYSE:AVTR traded down $0.20 during mid-day trading on Tuesday, hitting $13.92. 1,990,175 shares of the company’s stock traded hands, compared to its average volume of 3,054,546. The firm’s 50 day moving average price is $15.04. Avantor has a 12 month low of $13.33 and a 12 month high of $19.58.

Avantor (NYSE:AVTR) last announced its earnings results on Tuesday, August 6th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.03). The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.52 billion. The firm’s quarterly revenue was up 3.7% on a year-over-year basis. On average, research analysts predict that Avantor will post 0.57 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVTR. Coastal Investment Advisors Inc. acquired a new stake in shares of Avantor in the 2nd quarter valued at $69,000. JPMorgan Chase & Co. acquired a new stake in shares of Avantor in the 2nd quarter valued at $103,000. Russell Investments Group Ltd. acquired a new stake in shares of Avantor in the 2nd quarter valued at $113,000. FTB Advisors Inc. acquired a new stake in shares of Avantor in the 2nd quarter valued at $127,000. Finally, Tower Research Capital LLC TRC acquired a new stake in shares of Avantor in the 2nd quarter valued at $179,000. 73.48% of the stock is owned by institutional investors.

About Avantor

Avantor, Inc is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services.

Featured Article: What is diluted earnings per share (Diluted EPS)?

Get a free copy of the Zacks research report on Avantor (AVTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

KUEHNE & NAGEL/ADR  Stock Price Down 1.9%
KUEHNE & NAGEL/ADR Stock Price Down 1.9%
Siebert Financial  Trading Up 0.9%
Siebert Financial Trading Up 0.9%
BK CHINA LTD/ADR   Shares Down 0.9%
BK CHINA LTD/ADR Shares Down 0.9%
AA   Shares Down 0.4%
AA Shares Down 0.4%
Russell A. Colombo Sells 500 Shares of Bank of Marin Bancorp  Stock
Russell A. Colombo Sells 500 Shares of Bank of Marin Bancorp Stock
BioLife Solutions Inc  Major Shareholder Casdin Partners Master Fund, L Acquires 20,000 Shares
BioLife Solutions Inc Major Shareholder Casdin Partners Master Fund, L Acquires 20,000 Shares


© 2006-2019 Ticker Report